Skip to main content
SpringerLink
Log in

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Osteoporosis is prevalent in men with an estimated one in eight men older than 50 years suffering from osteoporotic fracture, and a higher mortality rate after fracture among men compared with women. There are few approved therapies for osteoporosis in men. This observational study assesses the efficacy and safety of risedronate in the treatment of men with primary and secondary osteoporosis. A single-center, open label, randomized, prospective 1-year study was conducted in men with primary or secondary osteoporosis. Patients were randomized to risedronate (risedronate 5 mg/day plus calcium 1,000 mg/day and vitamin D 800 IU/day) or control groups (alfacalcidol 1 μg/day plus calcium 500 mg/day or vitamin D 1,000 IU/day plus calcium 800 mg/day). Bone mineral density (BMD) measurements, X-rays of the spine, a medical history and physical exam, and patient self-assessments of back pain were performed at baseline and 12 months. Blinded semi-quantitative fracture assessment was conducted by a radiologist. A total of 316 men with osteoporosis were enrolled in the trial (risedronate, n=158; control, n=158). At 1 year lumbar spine BMD increased by 4.7% in the risedronate group versus an increase of 1.0% in the control group (P<0.001). Significant increases in BMD at the total hip and femoral neck were also observed with risedronate compared with the control group. The incidence of new vertebral fracture in the risedronate group was reduced by 60% versus the control group (P=0.028). Daily treatment with risedronate for 12 months significantly increased BMD at the lumbar spine, femoral neck and total hip and significantly reduced the incidence of new vertebral fractures. This is the first prospective, randomized, controlled trial to demonstrate a significant reduction in vertebral fractures in 1 year in men with primary or secondary osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Barrett-Connor E (1995) The economic and human costs of osteoporotic fracture. Am J Med 98(2A):3S–8S

    Article  PubMed  CAS  Google Scholar 

  2. Campion JM, Maricic MJ (2003) Osteoporosis in men. Am Fam Physician 67(7):1521–1526

    PubMed  Google Scholar 

  3. Center JR et al (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156):878–882

    Article  PubMed  CAS  Google Scholar 

  4. Olszynski WP et al (2004) Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26(1):15–28

    Article  PubMed  Google Scholar 

  5. Kiebzak GM et al (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162(19):2217–2222

    Article  PubMed  Google Scholar 

  6. Nguyen TV, Center JR, Eisman JA (2004) Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 180(5 Suppl):S18–S22

    PubMed  Google Scholar 

  7. Snyder PJ et al (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85(8):2670–2677

    Article  PubMed  CAS  Google Scholar 

  8. Orwoll E et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343(9):604–610

    Article  PubMed  CAS  Google Scholar 

  9. Ringe JD, Orwoll E, Daifotis A, Lombardi A (2002) Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13:195–199

    Article  PubMed  CAS  Google Scholar 

  10. Ringe JD, Dorst A, Faber H, Ibach K (2004) Alendonate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24:110–113

    Article  PubMed  CAS  Google Scholar 

  11. Physicians’ desk reference: PDR (2003) 57th edn. Thomson PDR, Montvale, p 3550

  12. Roux C et al (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20(4):433–439

    Article  PubMed  CAS  Google Scholar 

  13. Harrington T et al (2004) Risedronate rapidly reduces the risk for non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135

    Article  PubMed  CAS  Google Scholar 

  14. McClung MR et al (2001) Effect of risedronate on the risk of hip fracture in elderly women Hip Intervention Program Study Group. N Engl J Med 344(5):333–340

    Article  PubMed  CAS  Google Scholar 

  15. Reid DM et al (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69(4):242–247

    Article  PubMed  CAS  Google Scholar 

  16. Lindsay R et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285(3):320–323

    Article  PubMed  CAS  Google Scholar 

  17. Ringe JD (2000) Osteoporosis in men. In: Hosking D, Ringe J (eds) Treatment of metabolic bone disease. Management strategy and drug therapy. Martin Dunitz, London

  18. Hasserius R et al (2003) Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 4(1):61–68

    Article  Google Scholar 

  19. Ross PD et al (1991) Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114(11):919–923

    PubMed  CAS  Google Scholar 

  20. Harris ST et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352

    Article  PubMed  CAS  Google Scholar 

  21. Reginster J et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik 4, Allgemeine Innere (Rheumatology/Osteology), Klinikum Leverkusen, Akademisches Lehrkrankenhaus der Universität zu Köln, 51375, Leverkusen, Germany

    J. D. Ringe, H. Faber, P. Farahmand & A. Dorst

Authors
  1. J. D. Ringe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Faber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Farahmand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Dorst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. D. Ringe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ringe, J., Faber, H., Farahmand, P. et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26, 427–431 (2006). https://doi.org/10.1007/s00296-005-0004-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-005-0004-4

Keywords

Search

Navigation